Targeted Genetics said today it has found a way to conserve its remaining cash reserves a few more months, through the first half of 2009. The Seattle-based biotech company (NASDAQ: [[ticker:TGEN]]) is transferring its manufacturing know-how of AAV viruses for delivering gene therapy drugs to contract manufacturers, and renegotiated its partnership with La Jolla, CA-based Celladon to give that company expanded use to manufacture the AAVs for heart failure. In November, the company said it only had enough cash left to run “into the first quarter of 2009.”
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
